Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+ breast cancer

The current standard of care for many patients with HER2-positive breast cancer is neoadjuvant chemotherapy in combination with anti-HER2 agents, based on HER2 amplification as detected by in situ hybridization (ISH) or protein immunohistochemistry (IHC). However, hematoxylin & eosin (H&E) t...

Descripción completa

Detalles Bibliográficos
Autores principales: Farahmand, Saman, Fernandez, Aileen I., Ahmed, Fahad Shabbir, Rimm, David L., Chuang, Jeffrey H., Reisenbichler, Emily, Zarringhalam, Kourosh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221954/
https://www.ncbi.nlm.nih.gov/pubmed/34493825
http://dx.doi.org/10.1038/s41379-021-00911-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221954/
https://www.ncbi.nlm.nih.gov/pubmed/34493825
http://dx.doi.org/10.1038/s41379-021-00911-w

Ejemplares similares